Bringing new energy to the treatment of Type 2 Diabetes
Committed to improving the treatment of Type 2 Diabetes
Endogenex is creating a novel approach to address the challenges that Type 2 Diabetes brings to patients, providers and healthcare systems around the world.
Through a partnership with Mayo Clinic, Endogenex, has developed the ReCETTM Procedure, based on the principle of metabolic change through Intestinal Cellular Regeneration (ICR). The ReCET Procedure is investigational and under evaluation in clinical studies. The procedure is designed to promote better blood glucose control and potentially slow the progression of Type 2 Diabetes.
The ReCET ICR Procedure applies the unique capabilities of pulsed electric fields with a novel endoscopic approach that together are intended to restore the natural signaling process of the duodenum that helps the body better control blood glucose levels.
Through this outpatient procedure, Endogenex aims to provide patients with better blood glucose control, give providers a non-pharmacologic treatment option for their patients and reduce the burden that Type 2 Diabetes places on global healthcare systems.
“There needs to be a paradigm shift in the way we treat diabetes, from focusing on the downstream effects…to trying to reset the metabolic clock and push back the natural disease process.”
— Barham K. Abu Dayyeh, M.D., M.P.H.
Co-inventor, ReCET Technology